Filing Flows › Comparisons › ARWR vs HROW
Arrowhead Pharmaceuticals vs Harrow: ARWR and HROW compared
Arrowhead Pharmaceuticals is the larger company: $75.3M of revenue in its latest quarter (Q3 FY26) against $70.7M for Harrow (Q2 2026). Arrowhead Pharmaceuticals is growing faster (+171% against +11% a year earlier). Harrow is more profitable, with an operating margin of -15.6% against -226.0%.
Where the money goes: ARWR and HROW
Arrowhead Pharmaceuticals (ARWR) · Q3 FY26
Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart follows the revenue to costs, profit and cash.
Harrow (HROW) · Q2 2026
Harrow, Q2 2026: revenue $70.7M (+11% year over year), operating margin -15.6%, net loss $17.3M, operating cash flow −$9.8M. The chart follows the revenue to costs, profit and cash.
| Arrowhead Pharmaceuticals (ARWR) | Harrow (HROW) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q2 2026 |
| Revenue | $75.3M | $70.7M |
| Revenue growth, Y/Y | +171% | +11% |
| Operating margin | -226.0% | -15.6% |
| Net earnings | −$179M | −$17.3M |
| Net margin | -237.8% | -24.4% |
| Operating cash flow | −$177M | −$9.8M |
Where the revenue comes from
Harrow
- Product sales, net: $70.6M (100%)
- Other revenues: $90K (0%)
Questions
Which is bigger, Arrowhead Pharmaceuticals or Harrow?
Arrowhead Pharmaceuticals is the larger company: $75.3M of revenue in its latest quarter (Q3 FY26) against $70.7M for Harrow (Q2 2026).
Is Arrowhead Pharmaceuticals or Harrow growing faster?
Arrowhead Pharmaceuticals is growing faster (+171% against +11% a year earlier).
Which is more profitable, Arrowhead Pharmaceuticals or Harrow?
Harrow is more profitable, with an operating margin of -15.6% against -226.0%.
More: Arrowhead Pharmaceuticals earnings · how Arrowhead Pharmaceuticals makes money · Harrow earnings · how Harrow makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 4, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.